Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura

Blood

Volumn 120, Issue 17, 2012, Pages 3603-3610

  Callewaert, Filip ^a   Roodt, Jan ^b,c   Ulrichts, Hans ^a   Stohr, Thomas ^a   Van Rensburg, Walter Janse ^b   Lamprecht, Seb ^b   Rossenu, Stefaan ^a   Priem, Sofie ^a   Willems, Wouter ^a   Holz, Josefin Beate ^a  

^a ABLYNX NV   (Belgium)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

^c Universitas Private Hospital   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CREATININE; HAPTOGLOBIN; HEMATOLOGIC AGENT; LACTATE DEHYDROGENASE; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; TROPONIN T; UNCLASSIFIED DRUG; UREA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR NANOBODY ALX 0681;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BABOON; BLEEDING; BLOOD ANALYSIS; BLOOD CELL COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; SCHISTOCYTIC HEMOLYTIC ANEMIA; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84868565430     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-420943     Document Type: Article

References (44)

1. Denis CV, Christophe OD, Oortwijn BD, Lenting PJ. Clearance of von Willebrand factor. Thromb Haemost. 2008;99(2):271-278. (Pubitemid 351230955)
2. Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost. 2005;3(8):1702-1709. (Pubitemid 41716556)
3. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92(11):3983-3996. (Pubitemid 28544310)
4. Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood. 2008;112(4):957-964.
5. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99(11):3971-3977. (Pubitemid 35332036)
6. Chung DW, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochemistry. 2002;41(37):11065-11070. (Pubitemid 35034007)
7. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578-1584. (Pubitemid 28536132)
8. Lenting PJ, Pegon JN, Groot E, de Groot PG. Regulation of von Willebrand factor-platelet interactions. Thromb Haemost. 2010;104(3):449-455.
9. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939-2950. (Pubitemid 26357374)
10. Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake JL. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood. 1987;69(2):625-628. (Pubitemid 17022038)
11. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 1991;87(4):1234-1240.
12. Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem. 2000;275(11):7539-7546. (Pubitemid 30159651)
13. Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood. 2002;100(3):778-785. (Pubitemid 34832601)
14. George JN. Evaluation and management of patients with thrombotic thrombocytopenic purpura. J Intensive Care Med. 2007;22(2):82-91. (Pubitemid 46548125)
15. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3(7):1432-1436. (Pubitemid 41725200)
16. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120(4):556-573.
17. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116(20):4060-4069.
18. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-18.
19. Kremer Hovinga JA, Meyer SC. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol. 2008;15(5):445-450.
20. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393-397.
21. Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs. Blood. 2011;118(3):757-765.
22. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446-448. (Pubitemid 23179389)
23. Van Bockstaele F, Holz J-B, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs. 2009;10(11):1212-1224.
24. Cataland SR, Peyvandi F, Mannucci PM, et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87(4):430-432.
25. Jilma B, Jilma P, Paulinska P, et al. Proof of concept for the anti-von Willebrand factor aptamer in patients with relapsing thrombotic thrombocytopenic purpura (TTP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):2290.
26. De Meyer SF, De MB, Deckmyn H, Vanhoorelbeke K. Von Willebrand factor: drug and drug target. Cardiovasc Hematol Disord Drug Targets. 2009;9(1):9-20.
27. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther. 2010;8(12):1689-1701.
28. Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood. 2010;116(12):2005-2010.
29. Fitzmaurice G, Laird N, Ware J, eds. Applied Longitudinal Analysis. Hoboken, NJ: Wiley-IEEE; 2004.
30. Kramer CY. Extension of multiple range tests to group correlated adjusted means. Biometrics. 1957;13(1):13-18.
31. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432-1435. (Pubitemid 13234018)
32. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78(6):1456-1461. (Pubitemid 17219507)
33. Lotta LA, Mariani M, Consonni D, et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol. 2010;151(5):488-494.
34. Lowe EJ, Werner EJ. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in children and adolescents. Semin Thromb Hemost. 2005;31(6):717-730.
35. Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? J Clin Apher. 2007;22(1):21-25. (Pubitemid 46407057)
36. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003;10(5):339-344. (Pubitemid 36936604)
37. Naqvi TA, Baumann MA, Chang JC. Post-operative thrombotic thrombocytopenic purpura: a review. Int J Clin Pract. 2004;58(2):169-172. (Pubitemid 38425747)
38. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60-68. (Pubitemid 36759636)
39. Abd-Elaziz K, Kamphuisen PW, Lyssens C, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of anti-Vwf Nanobody ALX-0681 after single and multiple subcutaneous administrations to healthy volunteers [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:1063.
40. Holz JB, Bartunek J, Barbato E, Vercruysse K, Pullan S, Heyndrickxs G. ALX-0081 a novel antithrombotic: first results of a multiple dose phase 1 study in patients with stable angina undergoing PCI [abstract]. J Thromb Haemost. 2009;7(Suppl 2):PP-WE-416.
41. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004;2004:407-423.
42. Lewis QF, Lanneau MS, Mathias SD, Terrell DR, Vesely SK, George JN. Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009;49(1):118-124.
43. Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood. 1992;79(10):2507-2519.
44. Stufano F, S LAM, Pontiggia S, Musallam KM, Peyvandi F. von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(4):728-730.